lifestyle.tweeternet.com

Author: FibroBiologics, Inc.

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

February 24, 2026
FibroBiologics Granted Extension by Nasdaq to Regain Compliance

February 23, 2026
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University

February 12, 2026
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

February 11, 2026